ArticleMicrobiology spectrum2025
Longitudinal phenotypic and genomic evidence revealing increased risk of drug resistance accumulation in tuberculosis patients in the counties of central China.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular epidemiology of drug-resistant tuberculosis in Jiangxi Province, China, 2022-2023.Global health & medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Drug-resistant tuberculosis (DR-TB) disproportionately affects rural China, yet the molecular and epidemiological drivers of this disparity remain inadequately explored. This study investigates resistance evolution and transmission dynamics in Xianning, China, using longitudinal data from 3,865 culture-positive pulmonary tuberculosis patients (2016-2023). Phenotypic drug susceptibility testing for 14 commonly used anti-tuberculosis drugs showed a stable multidrug-resistant tuberculosis (MDR-TB) rate of 6.6%, while mono-resistance increased from 8.5% to 12.9% over the study period. Notably, 19.3% (53/275) of patients with ≥2 months of culture positivity developed new phenotypic resistance during treatment. Whole-genome sequencing of strains from the last two years identified resistance accumulation through two additional mechanisms: (i) acquisition of resistance via unfixed mutations in individuals and (ii) transmitted strains harboring novel resistance-conferring mutations absent in parental clones within genomic clusters. For the combined cases of resistance accumulation, multivariable logistic regression revealed that baseline drug resistance increased the risk more than threefold (aOR = 3.65-5.28, varying by resistance type), while rural residence independently doubled the risk (aOR = 2.60, 95% confidence interval:1.11-6.49). Furthermore, three of five genomic clusters with resistance accumulation exhibited urban-rural transmission, highlighting risks linked to cross-district care-seeking. These findings underscore how systemic healthcare barriers in rural China drive DR-TB through both treatment failures and strain transmission. Urgent action is needed to decentralize rapid resistance screening and implement tiered care models in primary clinics to curb transmission and mitigate the expanding DR-TB threat.IMPORTANCEThe ongoing epidemic of drug-resistant tuberculosis (DR-TB) in resource-poor settings poses a major public health challenge. This study sheds light on the evolution of DR-TB and its community transmission dynamics in central rural China, suggesting that unequal healthcare may exacerbate resistance accumulation risks by driving acquired resistance through inadequate treatment as well as facilitating strain transmission with escalating drug resistance. These findings emphasize the critical need for decentralized, rapid drug-resistance screening, and enhanced diagnosis and treatment strategies in primary care settings, prioritizing vulnerable populations to curb this growing threat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.